Theratechnologies Inc. (NASDAQ:THTX) Sees Significant Increase in Short Interest

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 72,200 shares, an increase of 64.8% from the November 30th total of 43,800 shares. Based on an average daily volume of 72,500 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.4% of the company’s stock are short sold.

Theratechnologies Price Performance

Theratechnologies stock traded down $0.04 during mid-day trading on Friday, reaching $1.79. The stock had a trading volume of 100,697 shares, compared to its average volume of 52,512. The company has a market capitalization of $82.30 million, a price-to-earnings ratio of -17.90 and a beta of 1.42. Theratechnologies has a one year low of $1.08 and a one year high of $2.58. The company has a 50-day moving average price of $1.38 and a two-hundred day moving average price of $1.35.

Theratechnologies (NASDAQ:THTX) last issued its earnings results on Thursday, October 10th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. The firm had revenue of $22.60 million during the quarter. During the same quarter in the previous year, the company posted ($0.03) EPS. On average, equities research analysts anticipate that Theratechnologies will post 0.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Theratechnologies

An institutional investor recently raised its position in Theratechnologies stock. Cyndeo Wealth Partners LLC increased its holdings in shares of Theratechnologies Inc. (NASDAQ:THTX) by 26.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 131,311 shares of the company’s stock after purchasing an additional 27,191 shares during the quarter. Cyndeo Wealth Partners LLC owned 0.29% of Theratechnologies worth $163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.